Alopecia Areata
Conditions
Keywords
Alopecia areata, Alopecia universalis, Alopecia totalis, Tofacitinib, JAK inhibitor
Brief summary
The objective of this study is to assess the safety and efficacy of Tofacitinib in treating patients with extensive and recalcitrant Alopecia Areata (AA), along with to evaluate the economic impact of the patients that may be from changing in their quality of life. There are patients with severe AA who may have little or no improvement from the treatment by diphenylcyclopropenone (DPCP) or topical steroid with minoxidil but instead having positive response from the treatment with Janus kinase(JAK) inhibitor such as Tofacitinib or Ruxolitinib. For the best of my knowledge, there was no previous study in using Tofacitinib to treat severe AA before in Thailand.
Detailed description
Alopecia areata (AA) or spot baldness, is a condition in which hair falls off from areas of the body. It often happens on the scalp, causing a few bald spots and it may result in psychological stress even though people are generally healthy. AA is believed to be an autoimmune disease progressing from a breach in the immune privilege of the hair follicles that causes hair to fall out in small patches, it may remain unnoticeable until the patches eventually connect and then become noticeable. It can develop slowly, and also recur after years between occurrences. By standard AA treatment guideline, DPCP is the first treatment protocol and may follow with anthralin or minoxidil. This oldy but goody treatment gives a good result of 75% in spotty hair loss and 25% in total baldness. The new invention of treatment has been introduced in the past 2 years by using JAK inhibitor, an oral medicine such as Tofacitinib and Ruxolitinib. This treatment gives a good outcome so far in this short period of time, 54-81.9% of patients had over 50% increase of hair grows over the original protocol. The theory is that JAK inhibitors would inhibit interferon-gamma and interleukin-15 signal between white blood cell and hair follicle which reducing the rate of destroying hair follicles. The investigators propose the study to assess the safety and efficacy of Tofacitinib for extensive and recalcitrant AA and to evaluate the economic impact effecting the AA patients. Tofacitinib is an expensive medicine and needed to be taken up to 6 months to finish the course to have a best outcome so it is not a popular choice of AA treatment at present time unless it can show a promising result in recalcitrant AA.
Interventions
DRUGTofacitinib
Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
Sponsors
Institute of Dermatology, Thailand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a Cohort study which all recruited volunteers will receive Tofacitinib for total of 24 weeks. The 19 volunteers are mixed male and female Thais who suffer from severe AA over 50% of the entire scalp.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Thai volunteers age between 18 and 60 years old. * Volunteers must be patients who suffer from severe AA more than 50% of the entire scalp. * Volunteers must be patients who are able to complete the monthly treatment at least in the first 6 months.
Exclusion criteria
* Patients who suffer from other hair diseases such as: Telogen effluvium, Trichotillomania, Tinea capitis * Patients who have other diseases that can have an impact on hair loss or temporary hair loss condition with in 6 months prior to the study such as: thyroid problems, liver disease, malnutrition, hearth disease, neurological disease, gastrointestinal disorders, sexually transmitted disease, cancer, psychiatric disease. * Patients with AA who received treatment with either steroid, Anthralin or DPCP application within 1 month before the selection or patients who had oral or injection from steroid or other medication for hair loss treatment within 3 months before the selection. * Woman with pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Responders vs Non-Responders Using SALT Score | 48 weeks | The Severity of Alopecia Tool (SALT) is a measurement procedure used by dermatologists to determine the percentage of scalp hair loss. The SALT system divides the scalp into 4 areas: Top has 4 sections of 10% total are 40%, back has 4 sections of 6% total are 24% and the 2 sides, left and right, each has 2 sections of 4% and 2 sections of 5% total of 18% and 36% combined. In the beginning, the area of hair loss would be measured by checking each area for hair loss and determining the bald spots combined per SALT scale then keeping the record as SALT baseline (SALT). The total SALT score is measured 0-100%, with higher values representing greater hair loss. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side Effects From Tofacitinib | 48 weeks | Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48. |
Countries
Thailand
Participant flow
Pre-assignment details
Nineteen participants who met the inclusion criteria were enrolled and received 10 mg/day oral tofacitinib.
Participants by arm
| Arm | Count |
|---|---|
| Tofacitinib All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
Tofacitinib is the Janus kinase inhibitor, which FDA has approved for Rheumatoid Arthritis. It can inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the causes of hair loss. | 19 |
| Total | 19 |
Baseline characteristics
| Characteristic | Tofacitinib |
|---|---|
| Age, Continuous | 32.68 years STANDARD_DEVIATION 8.75 |
| Baseline SALT score | 95.11 score STANDARD_DEVIATION 14.24 |
| Race/Ethnicity, Customized Asian | 19 participants |
| Region of Enrollment Thailand | 19 Participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 19 |
| other Total, other adverse events | 9 / 19 |
| serious Total, serious adverse events | 1 / 19 |
Outcome results
Primary
Number of Responders vs Non-Responders Using SALT Score
The Severity of Alopecia Tool (SALT) is a measurement procedure used by dermatologists to determine the percentage of scalp hair loss. The SALT system divides the scalp into 4 areas: Top has 4 sections of 10% total are 40%, back has 4 sections of 6% total are 24% and the 2 sides, left and right, each has 2 sections of 4% and 2 sections of 5% total of 18% and 36% combined. In the beginning, the area of hair loss would be measured by checking each area for hair loss and determining the bald spots combined per SALT scale then keeping the record as SALT baseline (SALT). The total SALT score is measured 0-100%, with higher values representing greater hair loss.
Time frame: 48 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tofacitinib | Number of Responders vs Non-Responders Using SALT Score | Responders (SALT score improved >=50%) | 9 Participants |
| Tofacitinib | Number of Responders vs Non-Responders Using SALT Score | Non-responders (SALT score improved < 50%) | 10 Participants |
Secondary
Side Effects From Tofacitinib
Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48.
Time frame: 48 weeks
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tofacitinib | Side Effects From Tofacitinib | Myalgia | 1 participants |
| Tofacitinib | Side Effects From Tofacitinib | Acne | 2 participants |
| Tofacitinib | Side Effects From Tofacitinib | Dyslipidemia | 9 participants |
| Tofacitinib | Side Effects From Tofacitinib | Upper respiratory tract infection | 6 participants |
| Tofacitinib | Side Effects From Tofacitinib | Tuberculosis | 1 participants |
| Tofacitinib | Side Effects From Tofacitinib | Weight gain | 1 participants |
| Tofacitinib | Side Effects From Tofacitinib | Constipation | 1 participants |